BB Biotech AG / Fundamentals
Income statement
- Net revenue
-€175.09M - Cost of goods sold
-€87.24M - Gross profit
-€87.85M - SG&A expenses
€29.99M - R&D expenses
€0.00 - EBITDA
-€85.21M - D&A
-€49.80M - EBIT
-€205.08M - Interest expenses
€2.99M - EBT
-€460.52M - Tax expenses
€60.61K - Net income
-€460.58M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€595.19M - Changes in working capital
€0.00 - Operating cash flow
€565.50M - Capex
€0.00 - Other investing cash flow
€0.00 - Net investing cash flow
€0.00 - Total cash dividends paid
-€106.60M - Issuance of common stock
€0.00 - Debt repayment
-€175.99M - Other financing cash flow
-€200.99M - Net financing cash flow
-€489.07M - Foreign exchange effects
-€913.52K - Net change in cash
€75.52M - Cash at end of period
€75.96M - Free cash flow
€565.50M
Balance sheet
- Cash and cash equivalents
€75.96M - Cash and short-term investments
€75.96M - Total receivables
€20.93M - Inventory
€0.00 - Other current assets
€2.01B - Total current assets
€2.11B - Property, plant & equipment
€0.00 - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€2.01B - Other non-current assets
-€2.01B - Total non-current assets
€0.00 - Total assets
€2.11B - Accounts payable
€0.00 - Short-term debt
€0.00 - Other current liabilities
€4.67M - Total current liabilities
€4.78M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€0.00 - Total liabilities
€4.78M - Common stock
€11.99M - Retained earnings
€2.14B - Other equity
€0.00 - Total equity
€2.10B - Total liabilities and shareholders' equity
€2.11B
Company information
- Market capitalization
€1.79B - Employees
10 - Enterprise Value
€1.83B
Company ratios
- Gross margin
-
50.2% Much worse than peer group: 91.4% - EBITDA margin
-
48.7% Much better than peer group: 19.2% - EBIT margin
-
117.1% Much better than peer group: 19.4% - EBT margin
-
263.0% Much better than peer group: 17.7% - Net margin
-
263.0% Much better than peer group: 14.2% - ROE
-
-21.9% Much worse than peer group: 38.9% - ROA
-
-21.8% Much worse than peer group: 19.7% - Asset turnover
-
-8.3% Much worse than peer group: 102.5% - FCF margin
-
-323.0% Much worse than peer group: 12.5% - FCF yield
31.6% - Efficiency ratio
51.3% - Net sales per employee
-
-€17.51M - Net income per employee
-
-€46.06M